Literature DB >> 31460996

Microsurgical Breast Reconstruction in the Obese: A Better Option Than Tissue Expander/Implant Reconstruction?

Kristen A Klement1, John B Hijjawi1, John A LoGiudice1, Mohammad Alghoul1, Pamela Omesiete-Adejare1.   

Abstract

BACKGROUND: Obesity has reached epidemic proportions, with 72 million people in the United States classified as obese in 2010. This significant increase in obese patients is reflected in the breast cancer population seeking breast reconstruction. Previous studies demonstrated increased complication rates and decreased satisfaction in obese patients undergoing breast reconstruction. This study aims to directly compare prosthetic and autologous reconstruction in the obese population by evaluating surgical outcomes and patient satisfaction.
METHODS: In an institutional review board-approved study, a retrospective chart review was conducted on patients with a body mass index of 30.0 kg/m or greater who underwent breast cancer reconstruction after mastectomy with either free tissue transfer from the abdomen or prosthetic reconstruction over a 3-year period. The authors identified 96 patients with 141 reconstructions. Demographic, intraoperative, and postoperative variables were collected. All patients were sent the BREAST-Q questionnaire by means of mail to study the impact and effectiveness of breast surgery from the patient's perspective. Statistical analysis was completed with Fisher's exact test, Mantel-Haenszel chi-square test, Pearson chi square test, or Mann-Whitney-Wilcoxon test.
RESULTS: Prosthetic-based breast reconstruction was associated with increased major breast complications (p < 0.001), mastectomy skin flap necrosis (p = 0.009), infection (0.006), and overall reconstructive failure (p < 0.0001) compared with autologous reconstruction. When evaluating the results of the BREAST-Q studies, the autologous reconstruction group had improved satisfaction with breasts (p < 0.0001), satisfaction with outcome (p = 0.01), psychosocial well-being (p = 0.007), and sexual well-being (p = 0.006).
CONCLUSION: In the obese population, reconstruction with free tissue transfer from the abdomen resulted in decreased complications of the breast reconstruction site and improved patient satisfaction with outcomes compared with prosthetic reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

Entities:  

Mesh:

Year:  2019        PMID: 31460996     DOI: 10.1097/PRS.0000000000005897

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  6 in total

Review 1.  Breast reconstruction in the high-risk population: current review of the literature and practice guidelines.

Authors:  Margaret S Roubaud; Joseph N Carey; Emma Vartanian; Ketan M Patel
Journal:  Gland Surg       Date:  2021-01

Review 2.  Systematic Review of Breast-Q: A Tool to Evaluate Post-Mastectomy Breast Reconstruction.

Authors:  Ishith Seth; Nimish Seth; Gabriella Bulloch; Warren M Rozen; David J Hunter-Smith
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-12-16

3.  Breast Reconstruction Completion in the Obese: Does Reconstruction Technique Make a Difference in Its Achievement?

Authors:  Christine Velazquez; Robert C Siska; Ivo A Pestana
Journal:  J Reconstr Microsurg       Date:  2021-03-31       Impact factor: 2.873

4.  Predictive risk factors of complications in different breast reconstruction methods.

Authors:  J S Palve; T H Luukkaala; M T Kääriäinen
Journal:  Breast Cancer Res Treat       Date:  2020-05-28       Impact factor: 4.872

5.  Muscle-sparing Latissimus Dorsi: A Safe Option for Postmastectomy Reconstruction in Extremely Obese Patients.

Authors:  Jean-Claude D Schwartz
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-10-22

Review 6.  Current Landscape: The Mechanism and Therapeutic Impact of Obesity for Breast Cancer.

Authors:  Chongru Zhao; Weijie Hu; Yi Xu; Dawei Wang; Yichen Wang; Wenchang Lv; Mingchen Xiong; Yi Yi; Haiping Wang; Qi Zhang; Yiping Wu
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.